News
Women’s pain is still not taken seriously, says Clue CEO
Due to taboos around women’s health, many people are still unaware of the gender health gap, Audrey Tsang believes
Women are still being told that what they are experiencing is not a big deal, the CEO of the period tracking app Clue has said, urging governments to address gender bias in healthcare.
Clue CEO, Audrey Tsang, said that women’s pain is routinely underestimated and normalised, leading to conditions, such as endometriosis, PMDD and PCOS, going undiagnosed for years.
This, she said, can have a profound impact not just on women’s mental health but on their overall quality of life.
“As women, when something changes, or something’s not quite right, we may not realise it,” Tsang said.
“We don’t know when to see a doctor and when we do see one, data shows we can’t get a diagnosis. It takes, for example, on average seven years to get an endometriosis diagnosis. It’s simply not acceptable.”
One in three women with a female health condition in the UK have been made to wait three years or longer for a diagnosis, with those on a low-income or from ethnic minority backgrounds having worse experiences of waiting for care.
Tsang said this happens because women’s health services are still seen as “lifestyle” or luxury services.
“This is fundamentally wrong. Having a period or having a hormone-related health condition is not just a lifestyle thing. It’s a true health and medical need.”
The gender health gap
Although research shows the gender health gap affects women worldwide, Tsang said that due to taboos around women’s health many people are still unaware of it.
“The stigma coupled with a lack of data means that we not only have a gender health gap, but an innovation gap as well.”
Clue’s latest feature, which allows users to input confirmed diagnoses for 21 different health conditions, aims to “move the needle” on women’s health and help researchers better understand female-specific health problems.
“Our aim is to create what will be the world’s largest data set that can match the menstrual and wider health symptom patterns of people with confirmed diagnoses with those who have the same patterns, but who don’t yet have a diagnosis,” explained Tsang.
“Part of what we are doing is bringing to light what is happening. When you do something as basic as period tracking, you’re externalising that experience.
“When, as women, we have the courage and vulnerability to speak openly about our health and externalise our experiences, that’s when things begin to change.”
The CEO stressed, however, that closing the gender health gap and ensuring women get the care they need will require a collective effort.
“It’s a movement. We all need to be involved on all sides of it, whether it’s as people, as patients or as healthcare systems.
“We need a complete ecosystem shift in order for things to change for the better.”
To receive the Femtech World newsletter, sign up here.
Diagnosis
Lung cancer drug shows breast cancer potential
Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.
PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.
Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.
The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.
In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.
Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.
Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.
Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”
John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”
Insight
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
Entrepreneur
Kindbody unveils next-gen fertility platform
-
Insight4 weeks agoDesigner perfumes recalled over banned chemical posing fertility risk
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Insight3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Insight4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Menopause3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Entrepreneur6 days agoUS startup builds wearable hormone tracker
-
Wellness2 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
Entrepreneur4 weeks agoVerdane invest in Clue to accelerate the future of women’s health






